Table S5. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• FoundationOne Liquid CDx effectively detects BRAF V600E in colorectal cancer, supporting clinical use.
• The estimated log(HR) difference for the F1LCDx+/CTA+ population is noted, confirming its clinical validity.
• Observational analysis shows significant alignment in detection metrics and patient outcomes.
• The findings highlight the potential of liquid biopsy technology in colorectal cancer diagnostics.